Cover Image
市場調查報告書

慢性阻塞性肺病 (COPD) - 至2023年的流行病學的預測

EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 347928
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
慢性阻塞性肺病 (COPD) - 至2023年的流行病學的預測 EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
出版日期: 2015年12月01日 內容資訊: 英文 73 Pages
簡介

由於 慢性阻塞性肺病 (COPD) ,是引起呼吸困難和呼吸急促、喘鳴、胸部壓迫感等症狀的疾病,根據WHO認為到2030年成為第3大死因。在全球8大市場中,慢性阻塞性肺病的患病數量預計從2013年的約6,423萬件以年率1.49%擴大,2023年增加到7,380萬。

本報告提供慢性阻塞性肺病的概要與風險因素、全球8大市場的趨勢,以及今後的流行病學的預測彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
  • 全球的趨勢
    • 美國
    • 歐洲5個國家
    • 日本及澳洲
  • 預測方法
    • 使用的資訊來源
    • 未使用的資訊來源
    • 預測方法與假設
  • 流行病學的預測
    • 患病數量
    • 各年齡患病數量
    • 性別患病數量
    • 年齡標準化數量
    • 各重度數量
    • 確診數量
    • 各年齡確診數量
    • 性別確診數量
    • 年齡評估確診數量
    • 各重度確診數量
    • 有共生病症的確診數量
    • 存活1年的確診數量
  • 考察
    • 流行病學的預測
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER105-15

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD. COPD is also a significant cause of morbidity and mortality, and the World Health Organization (WHO) predicts that it will be the third leading cause of death in the world by 2030.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 64,229,605 cases in 2013 to 73,794,089 cases in 2023 at an Annual Growth Rate (AGR) of 1.49%. GlobalData epidemiologists also forecast that the diagnosed prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage III, and 29.84% were in GOLD Stage IV. GlobalData epidemiologists estimated that 18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the end of the year.

This analysis for COPD is a market-driven epidemiological report providing detailed segmentations of the COPD patient population, including the age- and sex-specific distribution of the total and diagnosed prevalent cases, the GOLD stage distributions for the total and diagnosed prevalent cases, the diagnosed prevalent cases that have comorbidities, and an estimation of the exacerbations and mortality for the forecast COPD patients. GlobalData epidemiologists also describe in detail the sources and methodology that were used in the forecast, thereby ensuring transparency of the forecasting process.

Scope

  • The Chronic Obstructive Pulmonary Disease (COPD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for COPD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast of the total prevalent cases of COPD and total diagnosed prevalent cases of COPD, segmented by age and sex. Additionally it provides segmentation of diagnosed prevalent cases by severity using the GOLD standard.
  • The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The COPD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for COPD therapeutics in each of the markets covered.
  • Identify the COPD comorbidities that are most important to your marketing plans

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan and Australia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for COPD (2013-2023)
    • 3.5.1. Total Prevalent Cases of COPD
    • 3.5.2. Age-Specific Total Prevalent Cases of COPD
    • 3.5.3. Sex-Specific Total Prevalent Cases of COPD
    • 3.5.4. Age-Standardized Total Prevalence of COPD
    • 3.5.5. Total Prevalent Cases of COPD by the GOLD Severity Stage
    • 3.5.6. Diagnosed Prevalent Cases of COPD
    • 3.5.7. Age-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.8. Sex-Specific Diagnosed Prevalent Cases of COPD
    • 3.5.9. Age-Standardized Diagnosed Prevalence of COPD
    • 3.5.10. Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage
    • 3.5.11. Diagnosed Prevalent Cases of COPD with Comorbidities
    • 3.5.12. Diagnosed Prevalent Cases of COPD Surviving to One Year
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Physicians and Specialists Included in this Study
  • 4.3. About the Authors
    • 4.3.1. Epidemiologists
    • 4.3.2. Reviewers
    • 4.3.3. Global Director of Therapy Analysis and Epidemiology
    • 4.3.4. Global Head of Healthcare
  • 4.4. About GlobalData
  • 4.5. About EpiCast
  • 4.6. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for COPD
  • Table 2: GOLD COPD Severity Diagnostic Criteria
  • Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of COPD
  • Table 4: 8MM, Sources Used to Determine the Severity Segmentation Among the Total Prevalent Cases of COPD
  • Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosis Rate
  • Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosed Prevalence Rate
  • Table 7: 8MM, Sources Used to Forecast the Prevalent Cases of Comorbidities Among the Diagnosed Prevalent Cases of COPD
  • Table 8: 8MM, Sources Used to Forecast the GOLD Severity Among the Diagnosed Prevalent Cases of COPD
  • Table 9: 8MM, Sources Used to Forecast the Exacerbations and Mortality Among the Diagnosed Prevalent Cases of COPD by the GOLD Stage
  • Table 10: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023
  • Table 11: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N (Row %), 2013
  • Table 12: 8MM: Sex-Specific Total Prevalent Cases of COPD, Ages ≥35 Years, N (Row %), 2013
  • Table 13: 8MM, Total Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages ≥35 Years, N (Row %), 2013
  • Table 14: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023
  • Table 15: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013
  • Table 16: 8MM: Sex-Specific Diagnosed Prevalent Cases of COPD, Ages ≥35 Years, N (Row %), 2013
  • Table 17: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages ≥35 Years, N (Row %), 2013
  • Table 18: 8MM, Comorbidities Among the Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, 2013
  • Table 19: 8MM, Diagnosed Prevalent COPD Cases Experiencing Exacerbations and Mortality, Both Sexes, Ages ≥35, N, 2013

List of Figures

  • Figure 1: 8MM, Forecast Methodology Case Flow Overview
  • Figure 2: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023
  • Figure 3: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2013
  • Figure 4: 8MM, Sex-Specific Total Prevalent Cases of COPD, Ages ≥35 Years, N, 2013
  • Figure 5: 8MM, Age-Standardized Total Prevalence of COPD (%), 2013
  • Figure 6: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023
  • Figure 7: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013
  • Figure 8: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Ages ≥35 Years, 2013
  • Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Both Sexes, Ages ≥35 Years, 2013
  • Figure 10: 8MM, Diagnosed Prevalent COPD Cases Experiencing Mortality, Both Sexes, Ages ≥35 Years, N, 2013
Back to Top